{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:01:49Z","timestamp":1789189309008,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000046","name":"Abbott Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011026","name":"DUSA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Palmoplantar psoriasis is a variant of psoriasis vulgaris which can severely impair quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The main objectives of this double\u2010blind, placebo\u2010controlled, randomized study were to assess the efficacy and impact on quality of life and work productivity of apremilast for the treatment of moderate\u2010to\u2010severe palmoplantar psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 100 patients with moderate\u2010to\u2010severe palmoplantar psoriasis were randomized to either apremilast 30\u00a0mg bid or placebo for 16\u00a0weeks. At Week 16, all patients received apremilast 30\u00a0mg bid until Week 32. The primary endpoint was the proportion of patients who achieved a Palmoplantar Psoriasis Physician Global Assessment (<jats:styled-content style=\"fixed-case\">PPPGA<\/jats:styled-content>) of 0\/1 at Week 16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the proportion of patients who achieved a <jats:styled-content style=\"fixed-case\">PPPGA<\/jats:styled-content> of 0\/1 at Week 16 between patients randomized to apremilast (14%) and placebo (4%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.1595). After 32\u00a0weeks of treatment with apremilast, 24% of patients achieved a <jats:styled-content style=\"fixed-case\">PPGA<\/jats:styled-content> of 0\/1. In addition, apremilast was superior to placebo in achieving Palmoplantar Psoriasis Area Severity Index (<jats:styled-content style=\"fixed-case\">PPPASI<\/jats:styled-content>) 75 (apremilast: 22%; placebo: 8%; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0499), in improving <jats:styled-content style=\"fixed-case\">PPPASI<\/jats:styled-content> (apremilast: \u22127.4\u00a0\u00b1\u00a07.1; placebo: \u22123.6\u00a0\u00b1\u00a05.9; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0167), Dermatology Life Quality Index score (apremilast: \u22124.3\u00a0\u00b1\u00a05.1; placebo: \u22120.8\u00a0\u00b1\u00a04.5; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0004) and in reducing activity impairment (apremilast: \u221211.0\u00a0\u00b1\u00a022.3; placebo: 2.5\u00a0\u00b1\u00a025.5; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0063).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the absence of a significant difference between apremilast and placebo in proportion of patients achieving a <jats:styled-content style=\"fixed-case\">PPPGA<\/jats:styled-content> of 0\/1, the presence of significant differences observed for several secondary endpoints suggests that apremilast may have a role in the treatment of moderate\u2010to\u2010severe palmoplantar psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14647","type":"journal-article","created":{"date-parts":[[2017,10,21]],"date-time":"2017-10-21T12:32:37Z","timestamp":1508589157000},"page":"403-410","source":"Crossref","is-referenced-by-count":44,"title":["Apremilast for the treatment of moderate\u2010to\u2010severe palmoplantar psoriasis: results from a double\u2010blind, placebo\u2010controlled, randomized study"],"prefix":"10.1111","volume":"32","author":[{"given":"R.","family":"Bissonnette","sequence":"first","affiliation":[{"name":"Innovaderm Research Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haydey","sequence":"additional","affiliation":[{"name":"Winnipeg Clinic Winnipeg MB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Rosoph","sequence":"additional","affiliation":[{"name":"North Bay Dermatology Centre North Bay ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.W.","family":"Lynde","sequence":"additional","affiliation":[{"name":"Lynderm Research Markham ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bukhalo","sequence":"additional","affiliation":[{"name":"Altman Dermatology Associates Arlington Heights IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Dermatology Specialists Research Louisville KY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Delorme","sequence":"additional","affiliation":[{"name":"Dr Isabelle Delorme Inc. Drummondville QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gagn\u00e9\u2010Henley","sequence":"additional","affiliation":[{"name":"Dre Ang\u00e9lique Gagn\u00e9\u2010Henley MD Inc. Saint\u2010J\u00e9r\u00f4me QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Dr. Melinda Gooderham SKiN Centre for Dermatology Peterborough ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Poulin","sequence":"additional","affiliation":[{"name":"Centre de Recherche Dermatologique du Qu\u00e9bec M\u00e9tropolitain Qu\u00e9bec QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Barber","sequence":"additional","affiliation":[{"name":"Kirk Barber Research Calgary AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jenkin","sequence":"additional","affiliation":[{"name":"Dermatology Associates Seattle WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Landells","sequence":"additional","affiliation":[{"name":"Nexus Clinical Research St. John's NL Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology Eastern Virginia Medical School and Virginia Clinical Research Inc. Norfolk VA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)01479-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03197.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.03984.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.672710"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.02.1164"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.262"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04411.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_6_20_1","first-page":"AB221","article-title":"Minimal clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with adalimumab","volume":"54","author":"Melilli L","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:03:58Z","timestamp":1695549838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/jdv.14647"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14647","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}